The online version of this article (https://doi.org/10.1245/s10434-019-08074-4) contains supplementary material, which is available to authorized users.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Re-resection for incidental gallbladder cancer (iGBC) is associated with improved survival but little is known about residual disease (RD) and prognostic factors. In this study, survival after re-resection, RD, and prognostic factors are analyzed.
Patients with iGBC were identified from the Netherlands Cancer Registry, and pathology reports of re-resected patients were reviewed. Survival and prognostic factors were analyzed.
Overall, 463 patients were included; 24% (n = 110) underwent re-resection after a median interval of 66 days. RD was present in 35% of patients and was most frequently found in the lymph nodes (23%). R0 resection was achieved in 93 patients (92%). Median overall survival (OS) of patients without re-resection was 13.7 (95% confidence interval [CI] 11.6–15.6), compared with 52.6 months (95% CI 36.3–68.8) in re-resected patients (p < 0.001). After re-resection, median OS was superior in patients without RD versus patients with RD (not reached vs. 23.1 months; p < 0.001). In patients who underwent re-resection, RD in the liver (hazard ratio [HR] 5.54; p < 0.001) and lymph nodes (HR 2.35; p = 0.005) were the only significant prognostic factors in multivariable analysis. Predictive factors for the presence of RD were pT3 stage (HR 25.3; p = 0.003) and pN1 stage (HR 23.0; p = 0.022).
Re-resection for iGBC is associated with improved survival but remains infrequently used and is often performed after the optimal timing interval. RD is the only significant prognostic factor for survival after re-resection and can be predicted by pT and pN stages.
Are C, Ahmad H, Ravipati A, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol. 2017;115:580–90. CrossRef
Butte JM, Matsuo K, Gonen M, et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg. 2011;212:50–61. CrossRef
Lau CSM, Zywot A, Mahendraraj K, Chamberlain RS. Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973–2013). HPB Surg. 2017;2017:1532835. CrossRef
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602. CrossRef
Gil L, de Aretxabala X, Lendoire J, et al. Incidental gallbladder cancer: how residual disease affects outcome in two referral HPB centers from South America. World J Surg. 2019;43:214–20. CrossRef
Cavallaro A, Piccolo G, Panebianco V, et al. Incidental gallbladder cancer during laparoscopic cholecystectomy: managing an unexpected finding. World J Gastroenterol. 2012;18:4019–27. CrossRef
Dorobisz T, Dorobisz K, Chabowski M, et al. Incidental gallbladder cancer after cholecystectomy: 1990 to 2014. Onco Targets Ther. 2016;9:4913–6. CrossRef
Lundgren L, Muszynska C, Ros A, et al. Are incidental gallbladder cancers missed with a selective approach of gallbladder histology at cholecystectomy? World J Surg. 2018;42:1092–9. CrossRef
Soreide K, Guest RV, Harrison EM, et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy. Br J Surg. 2019;106:32–45. CrossRef
Steinert R, Nestler G, Sagynaliev E, et al. Laparoscopic cholecystectomy and gallbladder cancer. J Surg Oncol. 2006;93:682–9. CrossRef
Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17:681–90. CrossRef
Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11:1478–86. ( Discussion 1486-7). CrossRef
Butte JM, Kingham TP, Gonen M, et al. Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. J Am Coll Surg. 2014;219:416–29. CrossRef
Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg. 2011;35:1887–97. CrossRef
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7. CrossRef
Edge SB, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2010.
Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 2004.
Mackinnon A. The use and reporting of multiple imputation in medical research: a review. J Intern Med. 2010;268:586–93. CrossRef
Shirai Y, Yoshida K, Tsukada K, Muto T, Watanabe H. Early carcinoma of the gallbladder. Eur J Surg. 1992;158:545–8. PubMed
Wakai T, Shirai Y, Yokoyama N, et al. Early gallbladder carcinoma does not warrant radical resection. Br J Surg. 2001;88:675–8. CrossRef
Lundgren L, Muszynska C, Ros A, et al. Management of incidental gallbladder cancer in a national cohort. Br J Surg. 2019;106(9):1216–27. CrossRef
Hari DM, Howard JH, Leung AM, et al. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15:40–8. CrossRef
Abramson MA, Pandharipande P, Ruan D, Gold JS, Whang EE. Radical resection for T1b gallbladder cancer: a decision analysis. HPB (Oxford). 2009;11:656–63. CrossRef
Landelijke Werkgroep Gastro-intestinale tumoren (2013). Galweg-en galblaascarcinoom. Retrieved from https://www.oncoline.nl/galweg-en-galblaascarcinoom.
Ethun CG, Postlewait LM, Le N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US extrahepatic biliary malignancy consortium. JAMA Surg. 2017;152:143–9. CrossRef
Creasy JM, Goldman DA, Gonen M, et al. Predicting residual disease in incidental gallbladder cancer: risk stratification for modified treatment strategies. J Gastrointest Surg. 2017;21:1254–61. CrossRef
Ethun CG, Postlewait LM, Le N, et al. A novel pathology-based preoperative risk score to predict locoregional residual and distant disease and survival for incidental gallbladder cancer: a 10-institution study from the U.S. extrahepatic biliary malignancy consortium. Ann Surg Oncol. 2017;24:1343–50. CrossRef
- Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease
MD, PhD Elise A. J. de Savornin Lohman
PhD Lydia G. van der Geest
MSc Tessa J. J. de Bitter
MD, PhD Iris D. Nagtegaal
MD, PhD Cornelis J. H. M. van Laarhoven
MD, PhD Peter van den Boezem
MD, PhD Chella S. van der Post
MD, PhD Philip R. de Reuver
- Springer International Publishing
Annals of Surgical Oncology
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
Neu im Fachgebiet Chirurgie
Mail Icon II